May 08, 2020 / 05:00PM GMT
Operator
Good afternoon and welcome to AtriCure's Investor and Analyst Meeting in conjunction with HRS. My name is Stacy, and I will be your coordinator for the call today. (Operator Instructions) We will be facilitating a question-and-answer session toward the end of today's call. As a reminder, this call is being recorded for replay purposes.
I would now like to turn the call over to Lynn Lewis from Gilmartin Group for a few introductory comments.
Lynn Pieper Lewis - Gilmartin Group LLC - Founder & CEO
Thank you so much. Before we begin today, I'd like to remind everyone that as part of today's call, we will make certain comments about AtriCure's future expectations, plans and prospects that are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, expectations regarding the timing of FDA review, expectations regarding FDA's response and whether it will approve CONVERGE, the potential CONVERGE launch timing, the potential market opportunities for CONVERGE and
AtriCure Inc CONVERGE Trial Results -- Investor and Analyst Discussion Transcript
May 08, 2020
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers